Nishimura T, Sugita K, Aoki S, Takagi M
Department of Pediatrics, Osaka Medical College.
Jpn J Antibiot. 1995 Feb;48(2):191-9.
Clinical studies were carried out on SY5555, a new oral penem, in the field of pediatrics. The results obtained are summarized below. The clinical efficacies were examined in a total 31 patients consisting of 4 patients with pharyngitis, 10 with purulent tonsillitis, 4 with scarlet fever, 7 with impetigo, one with balanitis, one with cellulitis and 4 with UTI. The clinical efficacy rate was 96.8% (30/31). Bacteriological efficacies of SY5555 were examined on identified pathogens including 7 strains of Staphylococcus aureus, 6 of Streptococcus pyogenes, 3 of Enterococcus faecalis, 3 of Haemophilus influenzae, one of Escherichia coli and one of Citrobacter freundii. The bacteriological eradication rate was 81.0%. As for side effects, loose stool in one patient was noted. Abnormal laboratory findings test results included eosinophilia in 2 patients, eosinophilia and elevation of serum transaminase in one patient, and thrombocytosis in another.
对新型口服青霉烯类药物SY5555进行了儿科领域的临床研究。所得结果总结如下。共对31例患者进行了临床疗效检查,其中咽炎4例,化脓性扁桃体炎10例,猩红热4例,脓疱病7例,龟头炎1例,蜂窝织炎1例,尿路感染4例。临床有效率为96.8%(30/31)。对已鉴定的病原体检测了SY5555的细菌学疗效,这些病原体包括7株金黄色葡萄球菌、6株化脓性链球菌、3株粪肠球菌、3株流感嗜血杆菌、1株大肠杆菌和1株弗氏柠檬酸杆菌。细菌学根除率为81.0%。至于副作用,有1例患者出现腹泻。实验室检查结果异常包括2例患者嗜酸性粒细胞增多,1例患者嗜酸性粒细胞增多且血清转氨酶升高,另1例患者血小板增多。